EUVIMEDOpdag EUVIMED
VergleichsstudieKohortenstudieOpen access · CC BY-NC 4.0

A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre‐existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study

Elisabeth R Mathiesen iD, Amra Ciric Alibegovic, Gayathri Anil, Fidelma Dunne iD, Tariq Halasa, Marina Ivanišević, David R McCance, Rikke Baastrup Nordsborg, Peter Damm, EVOLVE study group

Diabetic Medicine · 2024

DOI: 10.1111/dme.15411 ↗

At a glance

Vergleichsstudie in Diabetic Medicine, 2024. Written by Elisabeth R Mathiesen and 9 co-authors. Institution: Center for Pregnant Women with Diabetes, Department of Endocrinology, Copenhagen, Denmark. Major MEDLINE topics: Diabetes Mellitus, Type 1, Insulin Aspart, Pregnancy in Diabetics, Hypoglycemic Agents. Cited 1 times so far (Crossref); 29 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

The safety and efficacy of insulin analogue insulin aspart (IAsp) have been demonstrated in a randomised clinical trial in pregnant women with Type 1 diabetes (T1D), and IAsp is widely used during pregnancy. The aim of this study was to assess glycaemic control and safety of IAsp versus other bolus insulins in Type 1 diabetic pregnancy in a real‐world setting.

Methods

This was a post hoc analysis of a prospective cohort study of 1840 pregnant women with T1D, treated with IAsp ( n = 1434) or other bolus insulins ( n = 406) in the Diabetes Pregnancy Registry. The primary (composite) outcome was the proportion of pregnancies resulting in major congenital malformations or perinatal or neonatal death. Secondary outcomes included all HbA 1c values measured immediately before and during pregnancy and major hypoglycaemia, as well as abortion, pre‐eclampsia, pre‐term delivery, large for gestational age at birth, stillbirth and fetal malformations.

Results

There were no significant differences found in any of the pregnancy outcomes between treatment with IAsp and other bolus insulins in either the crude or propensity score‐adjusted analyses. However, maternal HbA 1c was lower in the IAsp group at the end of the third trimester (adjusted difference, −0.16% point [95% CI −0.28;−0.05]; −1.8 mmol/mol [95% CI −3.1;−0.6]; p = 0.0046).

Conclusions

No significant differences in safety or pregnancy outcomes were demonstrated when comparing treatment with IAsp versus other bolus insulins in women with T1D during pregnancy. The observed improvement in HbA 1c with IAsp in late pregnancy should be confirmed in other studies.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 1Insulin AspartPregnancy in DiabeticsHypoglycemic AgentsPregnancy OutcomeGlycated HemoglobinHumansPregnancyFemaleAdultProspective StudiesHypoglycemiaInsulinInfant, NewbornCohort StudiesGlycemic ControlBlood Glucose

Author keywords

Type 1 diabetescohort studydiabetes pregnancy outcomesglycated haemoglobininsulin analoguesinsulin aspartpregnant women

Substances

Insulin AspartHypoglycemic AgentsGlycated HemoglobinInsulinhemoglobin A1c protein, humanBlood Glucose

Authors and institutions

  • Center for Pregnant Women with Diabetes, Department of Endocrinology, Copenhagen, Denmark.
  • Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Medical and Science, Novo Nordisk A/S, Søborg, Denmark.
  • Global Medical Affairs, Global Business Services (GMA-GBS), Novo Nordisk Service Centre India Private Limited, Bengaluru, India.
  • College of Medicine Nursing and Health Sciences, National University of Ireland Galway, Galway, Ireland.
  • Real-World Science-Diabetes, Novo Nordisk A/S, Søborg, Denmark.

ORCID profiles: Elisabeth R Mathiesen, Fidelma Dunne

Cite

APA

Mathiesen, E. R., Alibegovic, A. C., Anil, G., Dunne, F., Halasa, T., Ivanišević, M., McCance, D. R., Nordsborg, R. B., Damm, P., & EVOLVE study group (2024). A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre‐existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study. Diabetic Medicine. https://doi.org/10.1111/dme.15411

Vancouver

Mathiesen ER, Alibegovic AC, Anil G, Dunne F, Halasa T, Ivanišević M, et al. A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre‐existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study. Diabetic Medicine. 2024. doi:10.1111/dme.15411

BibTeX
@article{Mathiesen2024,
  author = {Mathiesen, Elisabeth R and Alibegovic, Amra Ciric and Anil, Gayathri and Dunne, Fidelma and Halasa, Tariq and Ivanišević, Marina and McCance, David R and Nordsborg, Rikke Baastrup and Damm, Peter and EVOLVE study group, EVOLVE study group},
  title = {A comparison of the safety and effectiveness of insulin aspart with other bolus insulins in women with pre‐existing Type 1 diabetes during pregnancy: A post hoc analysis of a prospective cohort study},
  journal = {Diabetic Medicine},
  year = {2024},
  doi = {10.1111/dme.15411}
}
Start for free →